{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T18:56:30Z","timestamp":1788893790630,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-91476-0","type":"journal-article","created":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T12:35:20Z","timestamp":1741178120000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pharmacovigilance analysis of immune checkpoint inhibitor-related reproductive adverse effects based on the FDA adverse event reporting system"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4462-6393","authenticated-orcid":false,"given":"Bahad\u0131r","family":"K\u00f6yl\u00fc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bu\u011fra Han","family":"Esen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eevval Nur","family":"Bekta\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"La\u015fin","family":"\u00d6zbek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkan","family":"Turan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00fclent","family":"Urman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1966-3886","authenticated-orcid":false,"given":"\u00d6zg\u00fcr","family":"\u00d6ktem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"Sel\u00e7ukbiricik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"key":"91476_CR1","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y Shiravand","year":"2022","unstructured":"Shiravand, Y. et al. Immune checkpoint inhibitors in Cancer therapy. Curr. Oncol. Tor. Ont. 29, 3044\u20133060 (2022).","journal-title":"Curr. Oncol. Tor. Ont."},{"key":"91476_CR2","doi-asserted-by":"publisher","first-page":"100276","DOI":"10.1016\/j.esmoop.2021.100276","volume":"6","author":"M Garutti","year":"2021","unstructured":"Garutti, M., Lambertini, M. & Puglisi, F. Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review. ESMO Open. 6, 100276 (2021).","journal-title":"ESMO Open."},{"key":"91476_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3389\/fphar.2017.00049","volume":"8","author":"V Kumar","year":"2017","unstructured":"Kumar, V. et al. Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Front. Pharmacol. 8, 49 (2017).","journal-title":"Front. Pharmacol."},{"key":"91476_CR4","doi-asserted-by":"publisher","first-page":"1167975","DOI":"10.3389\/fimmu.2023.1167975","volume":"14","author":"Q Yin","year":"2023","unstructured":"Yin, Q. et al. Immune-related adverse events of immune checkpoint inhibitors: a review. Front. Immunol. 14, 1167975 (2023).","journal-title":"Front. Immunol."},{"key":"91476_CR5","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-Related adverse events associated with immune checkpoint Blockade. N Engl. J. Med. 378, 158\u2013168 (2018).","journal-title":"N Engl. J. Med."},{"key":"91476_CR6","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1001\/jamaoncol.2020.1641","volume":"6","author":"JM Scovell","year":"2020","unstructured":"Scovell, J. M. et al. Association of impaired spermatogenesis with the use of immune checkpoint inhibitors in patients with metastatic melanoma. JAMA Oncol. 6, 1297\u20131299 (2020).","journal-title":"JAMA Oncol."},{"key":"91476_CR7","unstructured":"English | MedDRA. https:\/\/www.meddra.org\/how-to-use\/support-documentation\/english"},{"key":"91476_CR8","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman, K. J., Lanes, S. & Sacks, S. T. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 13, 519\u2013523 (2004).","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"91476_CR9","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate, A. & Evans, S. J. W. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 18, 427\u2013436 (2009).","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"91476_CR10","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1093\/annonc\/mdw696","volume":"28","author":"F Brunet-Possenti","year":"2017","unstructured":"Brunet-Possenti, F., Opsomer, M. A., Gomez, L., Ouzaid, I. & Descamps, V. Immune checkpoint inhibitors-related orchitis. Ann. Oncol. Off J. Eur. Soc. Med. Oncol. 28, 906\u2013907 (2017).","journal-title":"Ann. Oncol. Off J. Eur. Soc. Med. Oncol."},{"key":"91476_CR11","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1634\/theoncologist.2018-0722","volume":"24","author":"HT Quach","year":"2019","unstructured":"Quach, H. T. et al. Severe Epididymo-Orchitis and encephalitis complicating Anti-PD-1 therapy. Oncologist 24, 872\u2013876 (2019).","journal-title":"Oncologist"},{"key":"91476_CR12","doi-asserted-by":"publisher","first-page":"101488","DOI":"10.1016\/j.eucr.2020.101488","volume":"34","author":"MJ Rabinowitz","year":"2021","unstructured":"Rabinowitz, M. J. et al. Onset of azoospermia in man treated with Ipilimumab\/nivolumab for BRAF negative metastatic melanoma. Urol. Case Rep. 34, 101488 (2021).","journal-title":"Urol. Case Rep."},{"key":"91476_CR13","first-page":"41","volume":"152","author":"M Salzmann","year":"2021","unstructured":"Salzmann, M. et al. Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot study. Eur. J. Cancer Oxf. Engl. 1990. 152, 41\u201348 (2021).","journal-title":"Eur. J. Cancer Oxf. Engl. 1990"},{"key":"91476_CR14","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3389\/fimmu.2012.00152","volume":"3","author":"N Li","year":"2012","unstructured":"Li, N., Wang, T. & Han, D. Structural, cellular and molecular aspects of immune privilege in the testis. Front. Immunol. 3, 152 (2012).","journal-title":"Front. Immunol."},{"key":"91476_CR15","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.mce.2010.03.022","volume":"335","author":"A Meinhardt","year":"2011","unstructured":"Meinhardt, A. & Hedger, M. P. Immunological, paracrine and endocrine aspects of testicular immune privilege. Mol. Cell. Endocrinol. 335, 60\u201368 (2011).","journal-title":"Mol. Cell. Endocrinol."},{"key":"91476_CR16","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1095\/biolreprod.110.087452","volume":"84","author":"P Mital","year":"2011","unstructured":"Mital, P., Hinton, B. T. & Dufour, J. M. The blood-testis and blood-epididymis barriers are more than just their tight junctions. Biol. Reprod. 84, 851\u2013858 (2011).","journal-title":"Biol. Reprod."},{"key":"91476_CR17","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/978-1-60761-869-0_29","volume":"677","author":"M Fijak","year":"2011","unstructured":"Fijak, M., Bhushan, S. & Meinhardt, A. Immunoprivileged sites: the testis. Methods Mol. Biol. Clifton NJ. 677, 459\u2013470 (2011).","journal-title":"Methods Mol. Biol. Clifton NJ"},{"key":"91476_CR18","doi-asserted-by":"publisher","first-page":"12013","DOI":"10.1200\/JCO.2023.41.16_suppl.12013","volume":"41","author":"EI Buchbinder","year":"2023","unstructured":"Buchbinder, E. I. et al. Impact of immune checkpoint Inhibition on ovarian reserve in patients with melanoma enrolled in the ECOG-ACRIN E1609 adjuvant trial. J. Clin. Oncol. 41, 12013\u201312013 (2023).","journal-title":"J. Clin. Oncol."},{"key":"91476_CR19","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.jaad.2016.04.031","volume":"75","author":"JR Walter","year":"2016","unstructured":"Walter, J. R., Xu, S., Paller, A. S., Choi, J. N. & Woodruff, T. K. Oncofertility considerations in adolescents and young adults given a diagnosis of melanoma: fertility risk of food and drug Administration-approved systemic therapies. J. Am. Acad. Dermatol. 75, 528\u2013534 (2016).","journal-title":"J. Am. Acad. Dermatol."},{"key":"91476_CR20","doi-asserted-by":"publisher","first-page":"103799","DOI":"10.1016\/j.jri.2023.103799","volume":"156","author":"Z Chen","year":"2023","unstructured":"Chen, Z., Huang, J., Kwak-Kim, J. & Wang, W. Immune checkpoint inhibitors and reproductive failures. J. Reprod. Immunol. 156, 103799 (2023).","journal-title":"J. Reprod. Immunol."},{"key":"91476_CR21","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1530\/JOE-21-0209","volume":"252","author":"PC Xu","year":"2021","unstructured":"Xu, P. C. et al. Effects of PD-1 Blockade on ovarian follicles in a prepubertal female mouse. J. Endocrinol. 252, 15\u201330 (2021).","journal-title":"J. Endocrinol."},{"key":"91476_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s43018-022-00413-x","volume":"3","author":"AL Winship","year":"2022","unstructured":"Winship, A. L. et al. Checkpoint inhibitor immunotherapy diminishes oocyte number and quality in mice. Nat. Cancer. 3, 1\u201313 (2022).","journal-title":"Nat. Cancer"},{"key":"91476_CR23","doi-asserted-by":"publisher","first-page":"104064","DOI":"10.1016\/j.critrevonc.2023.104064","volume":"188","author":"H Tuerxun","year":"2023","unstructured":"Tuerxun, H. et al. Immune checkpoint inhibitors as a threat to reproductive function: A systematic review. Crit. Rev. Oncol. Hematol. 188, 104064 (2023).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"91476_CR24","doi-asserted-by":"crossref","unstructured":"Kciuk, M. et al. Recent advances in molecular mechanisms of Cancer immunotherapy. Cancers 15, 2721 (2023).","DOI":"10.3390\/cancers15102721"},{"key":"91476_CR25","doi-asserted-by":"publisher","first-page":"k4226","DOI":"10.1136\/bmj.k4226","volume":"363","author":"C Xu","year":"2018","unstructured":"Xu, C. et al. Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. BMJ 363, k4226 (2018).","journal-title":"BMJ"},{"key":"91476_CR26","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.eururo.2022.01.028","volume":"81","author":"Z Wu","year":"2022","unstructured":"Wu, Z. et al. Adverse events of immune checkpoint inhibitors therapy for urologic Cancer patients in clinical trials: A collaborative systematic review and Meta-analysis. Eur. Urol. 81, 414\u2013425 (2022).","journal-title":"Eur. Urol."},{"key":"91476_CR27","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1158\/2159-8290.CD-20-1312","volume":"11","author":"D Salas-Benito","year":"2021","unstructured":"Salas-Benito, D. et al. Paradigms on immunotherapy combinations with chemotherapy. Cancer Discov. 11, 1353\u20131367 (2021).","journal-title":"Cancer Discov"},{"key":"91476_CR28","doi-asserted-by":"publisher","first-page":"e23371","DOI":"10.1002\/jbt.23371","volume":"37","author":"JK Bhardwaj","year":"2023","unstructured":"Bhardwaj, J. K., Bikal, P. & Sachdeva, S. N. Chemotherapeutic drugs induced female reproductive toxicity and treatment strategies. J. Biochem. Mol. Toxicol. 37, e23371 (2023).","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"91476_CR29","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.3390\/ijms21041454","volume":"21","author":"M Delessard","year":"2020","unstructured":"Delessard, M. et al. Exposure to chemotherapy during childhood or adulthood and consequences on spermatogenesis and male fertility. Int. J. Mol. Sci. 21, 1454 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"91476_CR30","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ando.2023.03.009","volume":"84","author":"S De Leo","year":"2023","unstructured":"De Leo, S., Trevisan, M., Moneta, C. & Colombo, C. Endocrine-related adverse conditions induced by tyrosine kinase inhibitors. Ann. Endocrinol. 84, 374\u2013381 (2023).","journal-title":"Ann. Endocrinol."},{"key":"91476_CR31","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1080\/14737140.2019.1609355","volume":"19","author":"M Afshar","year":"2019","unstructured":"Afshar, M. et al. Chronic tyrosine kinase inhibitor (TKI) use in metastatic renal cell carcinoma (mRCC): can this lead to the adverse effect of hypogonadism? Expert Rev. Anticancer Ther. 19, 529\u2013532 (2019).","journal-title":"Expert Rev. Anticancer Ther."},{"key":"91476_CR32","doi-asserted-by":"publisher","unstructured":"Boskabadi, S. J., Dashti, A., Karevan, S., Kargar-Soleimanabad, S. & Salehifar, E. Clinical uses and safety concerns of tyrosine kinase inhibitors with a focus on novel drugs: A narrative review. J. Oncol. Pharm. Pract. Off Publ Int. Soc. Oncol. Pharm. Pract. 10781552231174790 https:\/\/doi.org\/10.1177\/10781552231174790 (2023).","DOI":"10.1177\/10781552231174790"},{"key":"91476_CR33","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nrc3237","volume":"12","author":"M Vanneman","year":"2012","unstructured":"Vanneman, M. & Dranoff, G. Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer. 12, 237\u2013251 (2012).","journal-title":"Nat. Rev. Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91476-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91476-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91476-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T12:35:25Z","timestamp":1741178125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91476-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["91476"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-91476-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7770"}}